International journal of nanomedicine2026ResearchDrug Delivery
Duan D, Xu S, Wu K, Xu M, Zhou S, Yang X, Et Al.
The blood-brain barrier (BBB) is a major bottleneck for nanomedicine-based treatment of central nervous system (CNS) disorders. Lactobacillus -derived extracellular vesicles (LEV) are promising biocompatible nanocarriers, but their low production yield and limited BBB permeability hinder their development. We…
Read the article →Expert opinion on drug delivery2026ReviewDrug Delivery
Hernandez Pa, Moore Cj, Overby Ct, Benoit Dsw
Nanoparticle drug delivery systems (NP DDS) have transformed therapeutic delivery by improving drug stability, extending circulation time, and enabling targeted biodistribution. However, clinical translation remains limited by protein corona formation, immune recognition, and accelerated blood clearance following…
Read the article →Exploration (Beijing, China)2026ReviewDrug Delivery
Lin Yj, Komperda I
Although nanomedicines offer advanced formulation control and physicochemical characterization, clinical translation has been limited. Delivery meta-analyses and late-stage attrition indicate biological validation is often a bottleneck. It must account for context-dependent processes such as protein corona formation…
Read the article →Expert opinion on drug delivery2026ReviewDrug Delivery
Gelperina S, Wacker Mg
Apolipoprotein E (apoE) plays a context-dependent role in nanomedicine for central nervous system drug delivery. It can facilitate cerebral endothelial recognition and increase brain exposure in nanoparticle systems while simultaneously promoting hepatic uptake, challenging its traditional interpretation as a…
Read the article →Pharmaceutics2026ReviewDrug Delivery
Syed Hashim Sa
Clinical translation of lipid nanomedicines in oncology is limited by biological barriers and by an interpretive challenge: tumour accumulation and cellular uptake are often used as proxies for delivery even when pharmacologically competent cargo, meaning cargo capable of producing its intended molecular effect, has…
Read the article →International journal of pharmaceutics2026ResearchDrug Delivery
Moltó-Abad M, Tomsen-Melero J, Villagrasa-Araya V, Marijuan-Pinel D, Díaz-Riascos Zv, Canals F, Et Al.
The protein corona (PC) formed upon nanoparticle exposure to blood critically defines their biological identity and in vivo fate, yet its impact on targeted liposomal enzyme replacement therapies (ERTs) remains incompletely understood. Here, we systematically investigated how RGD functionalization (including varying…
Read the article →Journal of controlled release : official journal of the Controlled Release Society2026ResearchNon-viral Gene DeliveryDrug Delivery
Jacobs W, De Zwaan K, Rutten L, Van Wessel T, Boltje Tj, Cano Lq, Et Al.
Non-viral nanocarriers for oligonucleotide delivery have enormous therapeutic potential, but the factors determining cell type-specific uptake remain incompletely understood. One major cell surface component that delivery vectors encounter is the glycocalyx. While membrane glycans are established interactors for many…
Read the article →